Physician profile
Grace Liu
NPI 1740994797
$4,125.42
in general payments reported to CMS, 2019-2025
24 companies · $838 in 2025
The $838 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,374 · 2024: $1,914 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,125.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $1,164.84 | 2023-2025 | Vowst, Zenpep |
| Abbvie INC. | $574.08 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $254.47 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $236.24 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $234.89 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $222.21 | 2023 | |
| Janssen Biotech, INC. | $178.68 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.97 | 2023-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $137.07 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $132.97 | 2023 | Zeposia |
| Lucid Diagnostics INC. | $125.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.34 | 2024-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $100.22 | 2023-2024 | Ocaliva |
| Lilly USA, LLC | $83.05 | 2025 | Omvoh |
| Celltrion USA INC. | $77.49 | 2024-2025 | Zymfentra, Vegzelma |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $73.10 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $59.39 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $36.35 | 2024 | Rebyota |
| Fresenius Kabi USA, LLC | $33.59 | 2023 | |
| Braintree Laboratories, INC. | $32.33 | 2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $32.07 | 2023 | Talicia |
| Phadia US INC. | $19.47 | 2023 | Immunocap |
| Organon LLC | $15.53 | 2023 | Hadlima |
| Ardelyx, INC. | $14.07 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.